5 Top NASDAQ Biotech Stocks: Delcath Systems Takes the Week

Delcath Systems, MannKind, Zogenix, BioLife Solutions and BioDelivery Sciences top the NASDAQ biotech stock list.

commodities investing

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) continued its decrease from the past few weeks by going down 0.93 decrease over the last five trading days and traded at 3,181.38 points. The Index is up 14.74 percent year-to-date.

Last week the Investing News Network (INN) reported on a new study indicating a dangerous majority of trials on revisions of previously approved devices by the US Food and Drug Administration (FDA) aren’t held to the standards that they should. The study looked at the approvals of devices between 2006 and 2015. Following the riots in Charlottesville, Virginia, the CEO of Merck (NYSE:MRKKenneth C. Frazier stepped down from president’s Trump special council of influencing CEO’s and business figures. This later resulted in a multitud of business leaders doing the same thing. Trump later tweeted he decided to disband the group altogether.

  • Delcath Systems (NASDAQ:DCTH)
  • MannKind (NASDAQ:MNKD)
  • Zogenix (NASDAQ:ZGNX)
  • BioLife Solutions (NASDAQ: BLFS)
  • BioDelivery Sciences (NASDAQ:BDSI)

Delcath Systems

Delcath Systems is a specialty pharmaceutical and medical device company. On August 8, the company shared its financial results for the second quarter of the year, indicating a 20 percent in increased revenue. However, there haven’t been any other news to cause the stock increase.

Delcath Systems gained 65.41 percent last week and closed the week at $0.15 per share.

MannKind

MannKind is a biopharmaceutical company that focuses on the development and commercialization of therapeutic products for patients with diabetes. On August 7, MannKind released their financial disclosure for the second quarter of the year in which it highlighted a net revenue growth of 29 percent for Afrezza. However, there haven’t been any other news to cause the stock increase.

MannKind gained 22.69 percent last week and closed the week at $1.46 per share.

Zogenix

Zogenix is a pharmaceutical company working on therapies for central nervous system disorders. The company shared their financial report for the second quarter on August 8. However, there haven’t been any other news to cause the stock increase.

Zogenix gained 19.51 percent last week and closed the week at $12.25 per share.

BioLife Solutions

BioLife Solutions is a manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media. On August 10 the company revealed their financials for the second quarter of 2017, in which the company explained their most recent growth thanks in part by sales of CryoStor and HypoThermosol clinical grade biopreservation media products to the regenerative medicine segment. However, there haven’t been any other news to cause the stock increase.

BioLife Solutions gained 4.35 percent last week and closed the week at $14.47 per share.

BioDelivery Sciences

BioDelivery Sciences is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. Last week the company announced it would be presenting three new posters reviewing the potential impacts of BELBUCA buccal film and BUNAVAIL buccal film on important issues pertinent to the opioid epidemic.

BioDelivery Sciences gained 3.30 percent last week and closed the week at $11.86 per share.

Don’t forget to follow @INN_LifeScience for real-time updates!

Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


** This article is updated each week. Please scroll to the top for the most recent information**

5 Top NASDAQ Biotech Stocks: Cytrx Leads the Week

August 13

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) continued its decrease from the past few weeks by going down 2.78 decrease over the last five trading days and traded at 3,211.31 points. The Index is up 15.82 percent year-to-date.

Last week the Investing News Network (INN) reported on FibroGen’s (NASDAQ:FGEN) massive increase in its stock value due to positive trial data idiopathic pulmonary fibrosis (IPF) drug pamrevlumab. As part of second quarter release season, Valeant Pharmaceuticals shared its sales stream totaled $2.23 billion, BioPharma DIVE reported the company has been facing manufacturing and legal troubles causing its decline this year. FiercePharma reported Mylan (NASDAQ:MYL) received subpoena from the Department of Justice looking into their opioid business. According to the report Mylan called the subpoena as “seeking informaion relating to opioids manufactured, marketed or sold by” the company from 2013 up until 2016.

AVEO Pharmaceuticals (NASDAQ:AVEO)

Staar Surgical (NASDAQ:STAA)

Vericel (NASDAQ:VCEL)

PDL BioPharma (NASDAQ:PDLI)

Natural Alternatives (NASDAQ:NAII)

AVEO Pharmaceuticals

AVEO is a biopharmaceutical company working on the development of oncology therapeutics. Last week the company released their financial results for the second quarter of 2017 in which it highlighted its recent advancements in upcoming trials and the recommendation of approval for tivozanib for advanced renal cell carcinoma.

AVEO Pharmaceuticals gained 15.02 percent last week and closed the week at $2.91 per share.

Staar Surgical

Staar develops implementable lenses for the eye to eliminate the need of glasses and contact lenses. Last week Staar also released their second quarter financial results in which their quarterly net sales went up 5 percent from last year to a total of $21.9 million, with only a reported $0.01 loss per share.

Staar Surgical gained 12.98 percent last week and closed the week at $11.75 per share.

Vericel

Vericel is a company with cell-based therapies, with three specific products in the US: MACI (autologous cultured chondrocytes on porcine collagen membrane), Carticel (autologous cultured chondrocytes), Epicel (cultured epidermal autografts). As part of their financial disclosure, the company reported $9.3 million in gross profits.

Vericel gained 12.90 percent last week and closed the week at $3.50 per share.

PDL BioPharma

PDL acquires and manages a portfolio of companies and products in the biotech, pharmaceutical and medical device sectors. The company also released their financial returns for the second quarter, with revenues totaling $143.8 million.

PDL BioPharma gained 11.72 percent last week and closed the week at $2.67 per share.

Natural Alternatives

Natural Alternatives is a formulator and manufacturer of customized nutritional supplements. The company was featured in several market blogs for its increase in stock activity on August 11. However, there haven’t been any other news to cause the stock increase.

Natural Alternatives gained 7.48 percent last week and closed the week at $10.48 per share.

Don’t forget to follow @INN_LifeScience for real-time updates!

Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Get the Latest Biotech Investing Stock Information

Get the latest information about companies associated with Biotech Investing delivered directly to your inbox.

Biotech

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Comments

Leave a Reply